Literature DB >> 17965582

Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity.

Tomoko Goto1, Junichiro Morioka, Hiroaki Inamura, Megumi Yano, Kazumi Kodaira, Yasushi Igarashi, Shyuzo Abe, Motohiro Kurosawa.   

Abstract

BACKGROUND: It has been reported that measurements of eosinophil-derived neurotoxin (EDN) may be useful for identifying eosinophil activities in allergic diseases including atopic dermatitis.
METHODS: EDN concentrations in the urine were measured by enzyme-linked immunosorbent assay, and the number of eosinophils in the peripheral blood was counted in 30 patients with atopic dermatitis. The severity of atopic dermatitis was graded on the criteria proposed by Rajka and Langeland. The disease activity was assessed by each patient on a visual analogue scale (VAS).
RESULTS: Urinary concentrations of EDN in patients with atopic dermatitis showed a significant positive correlation with disease severity. Urine EDN concentrations also correlated with VAS scores for itching, skin condition, overall skin symptoms and total VAS score, but not with the VAS score for skin dryness. Urinary EDN concentrations did not correlate with the number of eosinophils in the peripheral blood.
CONCLUSIONS: The urinary EDN concentration in patients with atopic dermatitis is a useful clinical marker for monitoring disease activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965582     DOI: 10.2332/allergolint.O-07-489

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  9 in total

Review 1.  IgE, mast cells, and eosinophils in atopic dermatitis.

Authors:  Fu-Tong Liu; Heidi Goodarzi; Huan-Yuan Chen
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

2.  Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study.

Authors:  Pradeep Tyagi; Derek Barclay; Ruben Zamora; Naoki Yoshimura; Kenneth Peters; Yoram Vodovotz; Michael Chancellor
Journal:  Int Urol Nephrol       Date:  2009-09-26       Impact factor: 2.370

3.  A fragment of the LG3 peptide of endorepellin is present in the urine of physically active mining workers: a potential marker of physical activity.

Authors:  Tony J Parker; Dayle L Sampson; Daniel Broszczak; Yee L Chng; Shea L Carter; David I Leavesley; Anthony W Parker; Zee Upton
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

4.  NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.

Authors:  Soo Rim Kim; Yeo Jung Moon; Sei Kwang Kim; Sang Wook Bai
Journal:  Yonsei Med J       Date:  2015-01       Impact factor: 2.759

5.  Association of FLG single nucleotide variations with clinical phenotypes of atopic dermatitis.

Authors:  Myungshin Kim; Jaeeun Yoo; Jiyeon Kim; Joonhong Park; Eunhee Han; Woori Jang; Hyojin Chae; Ji Hyun Lee; Young Min Park; Yonggoo Kim
Journal:  PLoS One       Date:  2017-12-27       Impact factor: 3.240

6.  Development of an automated ImmunoCAP research assay for eosinophil derived neurotoxin and its use in asthma diagnosis in children.

Authors:  Niclas Rydell; Mizuho Nagao; Helena Ekoff; Anders Sjölander; Magnus Borres; Takao Fujisawa
Journal:  Pract Lab Med       Date:  2019-09-19

7.  Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma.

Authors:  Chang-Keun Kim
Journal:  Korean J Pediatr       Date:  2013-01-29

8.  Variation in genes encoding eosinophil granule proteins in atopic dermatitis patients from Germany.

Authors:  Qumar Parwez; Susanne Stemmler; Jörg T Epplen; Sabine Hoffjan
Journal:  J Negat Results Biomed       Date:  2008-11-13

9.  A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children.

Authors:  You Hoon Jeon; Taek Ki Min; Hyeon Jong Yang; Bok Yang Pyun
Journal:  Allergy Asthma Immunol Res       Date:  2016-07       Impact factor: 5.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.